Herbal medicine treatment: Herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients
Life Guidance: Educational materials will be distributed, and education on daily life management for weight loss will be conducted. The educational materials consist of information on the definition and causes of obesity, explanations on weight reduction and daily life management applicable to various situations such as exercise and diet, and the effects of these practices.
Study summary
This study is a pragmatic pilot randomized controlled trial aimed at investigating the effectiveness of herbal medicine treatment for obese patients with spinal and joint pain, using a control group receiving lifestyle guidance.
Eligibility
Sex
ALL
Min age
19 Years
Max age
69 Years
Healthy volunteers
No
Inclusion Criteria:
* Patients aged 19 years or older but under 70 years.
* Individuals with a BMI of 25 kg/m² or higher, meeting the Asia-Pacific obesity criteria.
* Individuals experiencing spinal or joint pain, with the most severe pain rated as NRS 5 or higher.
* Individuals who voluntarily agree to participate in the clinical trial and sign the consent form.
Exclusion Criteria:
* Presence of findings on X-ray examination of the pain site, such as acute fractures or dislocations, requiring surgical intervention.
* Diagnosis of specific diseases that may cause secondary obesity (e.g., Cushing's syndrome, hypothyroidism, insulinoma, adult growth hormone deficiency, etc.).
* Current use of medications related to obesity treatment or a history of taking such medications within the past month.
* Presence of other chronic diseases that may interfere with treatment efficacy or interpretation of results, such as stroke, myocardial infarction, kidney disease, active hepatitis, diabetic neuropathy, dementia, epilepsy, etc.
* Current use of steroids, immunosuppressants, psychiatric medications, or other drugs that may affect study outcomes.
* Unsuitability or safety concerns for herbal medicine treatment: individuals with conditions or post-surgical complications affecting drug absorption or digestion, severe liver disease, or kidney disease.
* Pregnant or planning to become pregnant, or currently breastfeeding.
* Participation in other clinical trials, except for observational studies without therapeutic intervention.
* Difficulty in providing informed consent.
* Other cases where the investigator deems participation in the clinical study inappropriate.
Primary outcome measure(s)
BMI(Body Mass Index) — Change from baseline to Week 6 Body weight (kg) divided by the square of height (m) is used as a diagnostic criterion for obesity. Based on the significant increase in obesity-related diseases associated with body mass index (BMI), the Asia-Pacific region and the Korean Society for the Study of Obesity have established the criteria as follows: a BMI of 23 kg/m² or higher is classified as overweight or pre-obesity, and a BMI of 25 kg/m² or higher is classified as obesity.
Trial sites (1)
Facility
City
Region
Status
Jaseng Hospital of Korean Medicine
Seoul
Gangnam-Gu
More Jaseng Medical Foundation trials in South Korea
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.